Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1955 3
1956 1
1957 1
1958 3
1959 2
1960 2
1962 5
1963 4
1964 3
1965 4
1966 4
1967 10
1968 7
1969 4
1970 6
1971 5
1972 13
1973 6
1974 12
1975 15
1976 8
1977 13
1978 16
1979 25
1980 28
1981 30
1982 43
1983 50
1984 55
1985 44
1986 67
1987 61
1988 69
1989 76
1990 64
1991 62
1992 78
1993 65
1994 62
1995 83
1996 89
1997 76
1998 70
1999 96
2000 88
2001 104
2002 83
2003 93
2004 108
2005 116
2006 127
2007 126
2008 129
2009 141
2010 127
2011 172
2012 144
2013 141
2014 157
2015 127
2016 133
2017 154
2018 151
2019 162
2020 181
2021 226
2022 210
2023 192
2024 193
2025 97

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,693 results

Results by year

Filters applied: . Clear all
Page 1
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Salman P, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, John T, Carbone DP, Meadows-Shropshire S, Agrawal S, Oukessou A, Yan J, Reck M. Paz-Ares L, et al. Among authors: sakai h. Lancet Oncol. 2021 Feb;22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0. Epub 2021 Jan 18. Lancet Oncol. 2021. PMID: 33476593 Clinical Trial.
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.
Mazieres J, Paik PK, Garassino MC, Le X, Sakai H, Veillon R, Smit EF, Cortot AB, Raskin J, Viteri S, Wu YL, Yang JCH, Ahn MJ, Ma R, Zhao J, O'Brate A, Berghoff K, Bruns R, Otto G, Johne A, Felip E, Thomas M. Mazieres J, et al. Among authors: sakai h. JAMA Oncol. 2023 Sep 1;9(9):1260-1266. doi: 10.1001/jamaoncol.2023.1962. JAMA Oncol. 2023. PMID: 37270698 Free PMC article. Clinical Trial.
A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B).
Sakai H, Tsurutani J, Ozaki Y, Ishiguro H, Nozawa K, Yamanaka T, Aogi K, Matsumoto K, Iwasa T, Tokiwa M, Tsuneizumi M, Miyoshi Y, Kitagawa C, Yamamoto M, Takano Y, Imamura CK, Chiba Y, Takiguchi D, Ezumi T, Takano T. Sakai H, et al. Ann Oncol. 2025 Jan;36(1):31-42. doi: 10.1016/j.annonc.2024.09.001. Epub 2024 Sep 14. Ann Oncol. 2025. PMID: 39284382 Free article. Clinical Trial.
Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial.
Takahashi T, Yamanaka T, Seto T, Harada H, Nokihara H, Saka H, Nishio M, Kaneda H, Takayama K, Ishimoto O, Takeda K, Yoshioka H, Tachihara M, Sakai H, Goto K, Yamamoto N. Takahashi T, et al. Among authors: sakai h. Lancet Oncol. 2017 May;18(5):663-671. doi: 10.1016/S1470-2045(17)30230-9. Epub 2017 Mar 23. Lancet Oncol. 2017. PMID: 28343976 Clinical Trial.
Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.
Morise M, Kato T, Matsumoto S, Inoue T, Sakamoto T, Tokito T, Atagi S, Kozuki T, Takeoka H, Chikamori K, Shinagawa N, Tanaka H, Horii E, Adrian S, Bruns R, Johne A, Paik PK, Sakai H. Morise M, et al. Among authors: sakai h. Cancer Sci. 2024 Apr;115(4):1296-1305. doi: 10.1111/cas.16107. Epub 2024 Feb 25. Cancer Sci. 2024. PMID: 38402853 Free PMC article. Clinical Trial.
Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.
Kato T, Yang JC, Ahn MJ, Sakai H, Morise M, Chen YM, Han JY, Yang JJ, Zhao J, Hsia TC, Berghoff K, Bruns R, Vioix H, Lang S, Johne A, Le X, Paik PK. Kato T, et al. Among authors: sakai h. Br J Cancer. 2024 Jun;130(10):1679-1686. doi: 10.1038/s41416-024-02615-9. Epub 2024 Apr 4. Br J Cancer. 2024. PMID: 38575731 Free PMC article. Clinical Trial.
4,693 results